RAD140 (Testolone) | 120 x 5 mg

SAFETY DATA SHEET

Strictly for laboratory research use only. Not for human consumption.

RAD140 is the only compound in this class to have been given a proper drug name. It is now vosilasarm, and it has been through a first-in-human oncology trial — which makes it the most clinically advanced SARM after ostarine, and the one with the clearest liver signal in the published record. In that Phase 1 study, 59.1% of participants showed elevated AST and 45.5% elevated ALT. Both numbers belong on the same page as the efficacy data.

A compound with real clinical pharmacokinetics is only useful as a research material if the material matches. Every batch supplied by Max Muscle Labs is manufactured in the UK and verified to >99% purity by HPLC, with independent analysis before release.

Specifications

About the compound

RAD140 is a non-steroidal, orally active selective androgen receptor modulator, first described by Radius Health and later licensed to Ellipses Pharma as EP0062. It binds the androgen receptor with high affinity and acts as an agonist in muscle and bone while showing markedly weaker activity in prostate tissue — the tissue selectivity the class is named for.

Its research history has run along two separate tracks. The oncology track pursued RAD140 as an androgen-receptor-targeted therapy for AR-positive, ER-positive breast cancer, on the logic that AR agonism can suppress ER-driven tumour growth. The musculoskeletal track looked at anabolic and neuroprotective effects: RAD140 was reported to be neuroprotective in cultured neurons and in kainate-lesioned male rats (Jayaraman et al., 2014, Endocrinology).

It remains investigational and unapproved in every jurisdiction. Our full overview: what is RAD140 — research, studies and development.

What the published research shows

First-in-human Phase 1, metastatic breast cancer. Twenty-two heavily pretreated postmenopausal women with ER+/HER2− metastatic breast cancer, 21 of them AR-positive, received RAD140 at 50 mg (n=6), 100 mg (n=13) or 150 mg (n=3) once daily. The maximum tolerated dose was 100 mg/day. One patient with a baseline ESR1 mutation had a partial response; the clinical benefit rate at 24 weeks was 18.2% and median progression-free survival 2.3 months (NCT03088527).

Quality and verification

Independent analysis on every batch, before it reaches you:

• >99% purity confirmed by HPLC (high-performance liquid chromatography)
• Identity and structure confirmed by mass spectrometry, with contaminant screening
• Two independent rounds of analysis per batch
• UK manufacture to pharmaceutical-grade laboratory standards
• Certificate of Analysis supplied — see how to read a certificate of analysis

The specific reason verification matters for RAD140: because a clinical pharmacokinetic profile now exists at defined doses, this is one of the few compounds in the category where your results can be positioned against real human exposure data. That comparison collapses entirely if the material is a different compound or a different concentration — and RAD140 was one of the substances the published mislabelling analyses found substituted into products claiming to be something else. Our approach: the role of HPLC in compound testing and our UK certificate of analysis.

Research applications

Supplied as a characterised reference material for in-vitro and laboratory research, including:

• Androgen receptor binding affinity and agonism studies
• AR-positive breast cancer and hormone-receptor crosstalk models
• Neuroprotection and neuronal survival research models
• Hepatotoxicity and drug-induced liver injury mechanism studies, where the clinical signal warrants characterisation
• Comparative SARM pharmacology against ostarine and LGD-4033
• Analytical method development, assay calibration and reference standardisation
• Anti-doping detection and metabolite identification work

Storage and handling

Keep containers sealed, cool and out of direct light; solution and lyophilised presentations follow different stability curves and should be treated separately. Our 10-step storage guide and stability calculator cover UK research-setting practice, and laboratory PPE applies to any research chemical.

Frequently asked questions

What is RAD140?
A non-steroidal selective androgen receptor modulator, also known as testolone and now formally as vosilasarm, supplied here as a research-grade reference compound.

Why does RAD140 have a drug name?
Because it entered formal clinical development. Compounds that reach human trials receive an International Nonproprietary Name — vosilasarm — which is why you will see the two names used interchangeably in newer literature.

How does RAD140 compare to LGD-4033?
Both are high-affinity AR agonists. RAD140 has human oncology trial data and a documented hepatic signal; LGD-4033 has stronger lean-mass data from a Phase 2 hip-fracture study. Different evidence bases, not different potency classes.

Is RAD140 legal in the UK?
It is not licensed for human use and must not be marketed or sold for human consumption. It may be supplied for legitimate laboratory research. Detail: is RAD140 legal in 2026?

Is RAD140 detectable in anti-doping testing?
Yes. SARMs are prohibited at all times under WADA category S1.2 and RAD140 is detectable in standard screening — see can SARMs be detected in drug tests?

What purity do you supply?
>99% by HPLC, with mass-spectrometric identity confirmation, two independent analytical rounds per batch and a certificate of analysis.

Research reading

• What is RAD140? — research, studies and development history
• Does RAD140 increase or decrease testosterone?
• Is RAD140 legal? — the 2026 UK position
• Are SARMs hard on your liver?
• SARMs UK guide — the complete research overview
• Browse the full research compound range

Important compliance information

This product is supplied strictly for laboratory and analytical research use only. It is not a medicine, not a dietary supplement, and not for human or veterinary consumption. RAD140 is not approved by the MHRA, FDA, or any regulator for human use, and is prohibited in sport by WADA.

Max Muscle Labs does not provide dosing guidance, usage protocols, or any information implying human use. By purchasing, you confirm you are a qualified researcher or institution and will use this material in accordance with all applicable laws and research-conduct standards.

Sources

• PubChem — RAD140 / Vosilasarm (CID 44200882)
• First-in-human Phase 1 of RAD140 in ER+/HER2− metastatic breast cancer (NCT03088527)
• Hamilton et al., first-in-human Phase 1 study of RAD140, Clinical Breast Cancer
• Jayaraman et al. (2014), RAD140 neuroprotection, Endocrinology
• USADA — SARMs, prohibited class